Tello-Montoliu A, et al. - Focusing on the use of novel P2Y₁₂ receptor inhibitors, authors gauged how prognosis of acute coronary syndrome patients differs in those with and without chronic kidney disease (CKD). They assessed patients with acute coronary syndrome from 3 tertiary institutions, excluding anticoagulated patients and patients on antiplatelet monotherapy. Findings suggested an association of the use of third-generation P2Y₁₂ inhibitors among non-CKD patients with better outcomes in terms of major adverse cardiovascular events, all-cause mortality, and severe bleeding events, with no differences for any bleeding. No statistically significant lower mortality and thrombotic events were demonstrated by the CKD patients receiving third-generation P2Y₁₂ inhibitors. With the use of third-generation P2Y₁₂ inhibitors in either group of patients, bleeding risk was not increased.